Jacobio Pharmaceuticals Group Co., Ltd. repurchased 72,900 ordinary shares on 06 May 2026 through the Hong Kong Stock Exchange, paying an aggregate HKD 0.46 million at prices between HKD 6.30 and HKD 6.33 per share. The volume-weighted average repurchase price was HKD 6.32 per share.

Following the transaction, the company’s issued share base (excluding treasury shares) fell from 785.07 million to 784.99 million, while treasury shares increased from 6.68 million to 6.76 million. Total issued shares remained unchanged at 791.76 million.

The buyback represented 0.0093 % of the company’s outstanding shares prior to the repurchase. Cumulatively, 3.74 million shares have been repurchased under the mandate approved on 10 June 2025, utilising 0.474 % of the 78.87 million shares authorised for buyback.

In accordance with exchange rules, Jacobio Pharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 05 June 2026.